EF Hutton Acquisition Co. I Upgrades FibroBiologics (NASDAQ:FBLG) to Strong-Buy

FibroBiologics (NASDAQ:FBLG) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports.

FibroBiologics Stock Up 21.6 %

FBLG stock opened at $1.86 on Wednesday. The stock’s 50 day simple moving average is $3.42 and its 200 day simple moving average is $7.84. FibroBiologics has a fifty-two week low of $1.08 and a fifty-two week high of $55.00.

Institutional Trading of FibroBiologics

Hedge funds have recently bought and sold shares of the business. Mercer Global Advisors Inc. ADV bought a new position in shares of FibroBiologics in the second quarter valued at $51,000. Cahaba Wealth Management Inc. acquired a new position in FibroBiologics during the 2nd quarter valued at about $73,000. Saxon Interests Inc. purchased a new stake in shares of FibroBiologics in the second quarter worth approximately $106,000. Rhumbline Advisers bought a new position in shares of FibroBiologics in the second quarter valued at approximately $115,000. Finally, ERn Financial LLC purchased a new position in shares of FibroBiologics during the second quarter valued at approximately $159,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.